RT Journal Article
SR Electronic
T1 Molecular and Cellular Context Influences SCN8A Variant Function
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2023.11.11.566702
DO 10.1101/2023.11.11.566702
A1 Vanoye, Carlos G.
A1 Abramova, Tatiana V.
A1 DeKeyser, Jean-Marc
A1 Ghabra, Nora F.
A1 Oudin, Madeleine J.
A1 Burge, Christopher B.
A1 Helbig, Ingo
A1 Thompson, Christopher H.
A1 George, Alfred L.
YR 2023
UL http://biorxiv.org/content/early/2023/11/13/2023.11.11.566702.abstract
AB Pathogenic variants in SCN8A, which encodes the voltage-gated sodium (NaV) channel NaV1.6, are associated with neurodevelopmental disorders including epileptic encephalopathy. Previous approaches to determine SCN8A variant function may be confounded by the use of a neonatal-expressed alternatively spliced isoform of NaV1.6 (NaV1.6N), and engineered mutations to render the channel tetrodotoxin (TTX) resistant. In this study, we investigated the impact of SCN8A alternative splicing on variant function by comparing the functional attributes of 15 variants expressed in two developmentally regulated splice isoforms (NaV1.6N, NaV1.6A). We employed automated patch clamp recording to enhance throughput, and developed a novel neuronal cell line (ND7/LoNav) with low levels of endogenous NaV current to obviate the need for TTX-resistance mutations. Expression of NaV1.6N or NaV1.6A in ND7/LoNav cells generated NaV currents that differed significantly in voltage-dependence of activation and inactivation. TTX-resistant versions of both isoforms exhibited significant functional differences compared to the corresponding wild-type (WT) channels. We demonstrated that many of the 15 disease-associated variants studied exhibited isoform-dependent functional effects, and that many of the studied SCN8A variants exhibited functional properties that were not easily classified as either gain- or loss-of-function. Our work illustrates the value of considering molecular and cellular context when investigating SCN8A variants.Competing Interest StatementA.L.G. received research grant funding from Praxis Precision Medicines, Neurocrine Biosciences, and Biohaven Pharmaceuticals, and received research grant funding from and is a member of the Scientific Advisory Board for Tevard Biosciences.